A Secret Weapon For "3
All enrolled patients who acquired at the least one dose of zosuquidar or placebo all through induction were being monitored for your event of adverse gatherings (439 people, 219 on zosuquidar and 210 on placebo). The most common adverse activities were connected with the period of extended and substantial myelosuppression as is anticipated with in